• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    METHIONINE RESTRICTION
    September 12, 2021
    SGLT2 INHIBITION FOR LIFESPAN EXTENSION
    September 12, 2021
    1. The perils of portliness: causes and consequences of Visceral Adiposity.
    2. The clinical importance of Visceral Adiposity: a critical review of methods for Visceral adipose tissue analysis
    3. Visceral Adiposity Index: a reliable indicator of Visceral fat function associated with cardiometabolic risk
    4. Visceral Adiposity syndrome
    5. Relationship of obesity and Visceral Adiposity with serum concentrations of CRP, TNF-α and IL-6
    6. Is Visceral Adiposity the “enemy within”?
    7. Point: Visceral Adiposity is causally related to insulin resistance
    8. Measures of abdominal obesity assessed for Visceral Adiposity and relation to coronary risk
    9. Visceral Adiposity and the risk of metabolic syndrome across body mass index: the MESA Study
    10. Sex differences in inflammatory markers: what is the contribution of Visceral Adiposity?
    11. Visceral Adiposity, insulin resistance and cancer risk
    12. Predictive performance of the Visceral Adiposity index for a Visceral Adiposity-related risk: type 2 diabetes
    13. Visceral Adiposity index: an indicator of adipose tissue dysfunction
    14. Visceral Adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans.
    15. Visceral Adiposity as a target for the management of the metabolic syndrome
    16. Visceral Adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans
    17. Clinical significance of Visceral Adiposity assessed by computed tomography: a Japanese perspective
    18. Leptin selectively decreases Visceral Adiposity and enhances insulin action.
    19. Molecular evidence supporting the portal theory: a causative link between Visceral Adiposity and hepatic insulin resistance
    20. Visceral Adiposity is an independent predictor of incident hypertension in Japanese Americans
    21. Sleep apnoea and Visceral Adiposity in middle-aged male and female subjects
    22. Visceral Adiposity and the prevalence of hypertension in Japanese Americans
    23. Intestinal permeability is associated with Visceral Adiposity in healthy women
    24. The relationship between Visceral Adiposity and cognitive performance in older adults
    25. Cut-off points of the Visceral Adiposity index (VAI) identifying a Visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian …
    26. Adipocytokines attenuate the association between Visceral Adiposity and diabetes in older adults
    27. Maternal Visceral Adiposity by consistency of lactation
    28. Aortic stiffness is associated with Visceral Adiposity in older adults enrolled in the study of health, aging, and body composition
    29. Effect of growth hormone on body composition and Visceral Adiposity in middle-aged men with Visceral obesity
    30. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased Visceral Adiposity
    31. … between abdominal subcutaneous and Visceral Adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity …
    32. Effects of exercise intensity on cardiovascular fitness, total body composition, and Visceral Adiposity of obese adolescents
    33. Adipokines, inflammation, and Visceral Adiposity across the menopausal transition: a prospective study
    34. Effect of aerobic exercise training dose on liver fat and Visceral Adiposity
    35. Counterpoint: Visceral Adiposity is not causally related to insulin resistance
    36. Adiponectin in youth: relationship to Visceral Adiposity, insulin sensitivity, and β-cell function
    37. Relationship between Visceral Adiposity and bone mineral density in Korean adults
    38. Visceral Adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels
    39. Visceral Adiposity is associated with serum retinol binding protein‐4 levels in healthy women
    40. The Visceral Adiposity syndrome in Japanese‐American men
    41. Asian women have greater abdominal and Visceral Adiposity than Caucasian women with similar body mass index
    42. Gender‐specific anthropometric markers of Adiposity, metabolic syndrome and Visceral Adiposity index (VAI) in patients with obstructive sleep apnea
    43. Relationship of Visceral Adiposity to cardiovascular disease risk factors in black and white teens
    44. Fructose consumption: potential mechanisms for its effects to increase Visceral Adiposity and induce dyslipidemia and insulin resistance
    45. Dysregulation of the autonomic nervous system can be a link between Visceral Adiposity and insulin resistance
    46. An open-label pilot study to assess the efficacy and safety of virgin coconut oil in reducing Visceral Adiposity
    47. Rapid postnatal weight gain and Visceral Adiposity in adulthood: the Fels Longitudinal Study
    48. Visceral Adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans
    49. Age-related differences in inflammatory markers in men: contribution of Visceral Adiposity
    50. Sarcopenia, intramuscular fat deposition, and Visceral Adiposity independently predict the outcomes of hepatocellular carcinoma
    51. The application of Visceral Adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China
    52. Visceral Adiposity is negatively associated with bone density and muscle attenuation
    53. Visceral Adiposity in gastrointestinal and hepatic carcinogenesis
    54. … Visceral Adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and Visceral …
    55. Ten months of exercise improves general and Visceral Adiposity, bone, and fitness in black girls
    56. Testosterone replacement therapy improves insulin resistance, glycaemic control, Visceral Adiposity and hypercholesterolaemia in hypogonadal men with …
    57. Visceral Adiposity without overweight in children born small for gestational age
    58. Visceral Adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes
    59. Systemic oxidative alterations are associated with Visceral Adiposity and liver steatosis in patients with metabolic syndrome
    60. Central obesity as a clinical marker of adiposopathy; increased Visceral Adiposity as a surrogate marker for global fat dysfunction
    61. Genetic epidemiology of insulin resistance and Visceral Adiposity: the IRAS Family Study design and methods
    62. Visceral Adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community …
    63. Visceral Adiposity index is associated with significant fibrosis in patients with non‐alcoholic fatty liver disease
    64. The Visceral Adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome
    65. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, Visceral Adiposity, and insulin resistance?
    66. Dietary determinants of changes in waist circumference adjusted for body mass index–a proxy measure of Visceral Adiposity
    67. Usefulness of measuring both body mass index and waist circumference for the estimation of Visceral Adiposity and related cardiometabolic risk profile (from the …
    68. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low Visceral Adiposity
    69. White blood cell count in women: relation to inflammatory biomarkers, haematological profiles, Visceral Adiposity, and other cardiovascular risk factors
    70. Visceral Adiposity index is highly associated with adiponectin values and glycaemic disturbances
    71. Association of lifestyle factors with abdominal subcutaneous and Visceral Adiposity: the Framingham Heart Study
    72. Greater fructose consumption is associated with cardiometabolic risk markers and Visceral Adiposity in adolescents
    73. Breastfeeding and subsequent maternal Visceral Adiposity
    74. Adverse associations between Visceral Adiposity, brain structure, and cognitive performance in healthy elderly
    75. Visceral Adiposity is closely correlated with neck circumference and represents a significant indicator of insulin resistance in WHO grade III obesity
    76. Visceral Adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1
    77. General and Visceral Adiposity in black and white adolescents and their relation with reported physical activity and diet
    78. Applicability of the Visceral Adiposity index (VAI) in predicting components of metabolic syndrome in young adults
    79. In vivo quantification of subcutaneous and Visceral Adiposity by micro-computed tomography in a small animal model
    80. Consuming fructose-sweetened, not glucose-sweetened, beverages increases Visceral Adiposity and lipids and decreases insulin sensitivity in overweight …
    81. Visceral Adiposity index may be a surrogate marker for the assessment of the effects of obesity on arterial stiffness
    82. Change in Visceral Adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans
    83. Visceral Adiposity and hepatic steatosis at abdominal CT: association with the metabolic syndrome
    84. 4-year trajectory of Visceral Adiposity index in the development of type 2 diabetes: a prospective cohort study
    85. Inverse relation between dietary fiber intake and Visceral Adiposity in overweight Latino youth
    86. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high Visceral Adiposity index: a likely condition of cardiometabolic risk
    87. Abdominal Visceral Adiposity in the first trimester predicts glucose intolerance in later pregnancy
    88. Uteroplacental insufficiency increases Visceral Adiposity and Visceral adipose PPARγ2 expression in male rat offspring prior to the onset of obesity
    89. Association of subcutaneous and Visceral Adiposity with albuminuria: the Framingham Heart Study
    90. Visceral Adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS
    91. Quantitative measures of Visceral Adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation
    92. Echocardiographic assessment of epicardial adipose tissue-a marker of Visceral Adiposity
    93. Adipose tissue gene expression profiling reveals distinct molecular pathways that define Visceral Adiposity in offspring of maternal protein-restricted rats
    94. Inflammation mediates the association between Visceral Adiposity and obstructive sleep apnea in adolescents
    95. Identification of cardiometabolic risk: Visceral Adiposity index versus triglyceride/HDL cholesterol ratio
    96. Clinical usefulness of lipid ratios, Visceral Adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance
    97. Visceral Adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients
    98. Predictive value of Visceral Adiposity index for type 2 diabetes mellitus
    99. Lower growth hormone and higher cortisol are associated with greater Visceral Adiposity, intramyocellular lipids, and insulin resistance in overweight girls
    100. Earlier appearance of impaired insulin secretion than of Visceral Adiposity in the pathogenesis of NIDDM: 5-year follow-up of initially nondiabetic Japanese-American …
    101. Exposure to persistent organic pollutants: relationship with abnormal glucose metabolism and Visceral Adiposity
    102. Heart rate variability in obese children: relations to total body and Visceral Adiposity, and changes with physical training and detraining
    103. Erectile dysfunction is associated with low bioactive testosterone levels and Visceral Adiposity in men with type 2 diabetes
    104. Relationship between Visceral Adiposity and intramyocellular lipid content in two rat models of insulin resistance
    105. Association of Visceral Adiposity with oesophageal and junctional adenocarcinomas
    106. Applicatility of the Visceral Adiposity index (VAI) in the prediction of the components of the metabolic syndrome in elderly
    107. Does insulin resistance, Visceral Adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in women
    108. Significantly increased Visceral Adiposity index in prehypertension
    109. Visceral Adiposity index and risks of cardiovascular events and mortality in prevalent hemodialysis patients
    110. RAAS activation is associated with Visceral Adiposity and insulin resistance among HIV-infected patients
    111. Depressive symptoms are associated with Visceral Adiposity in a community‐based sample of middle‐aged women and men
    112. Visceral Adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009
    113. Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced Visceral Adiposity and insulin resistance
    114. Associations of Visceral Adiposity and exercise participation with C-reactive protein, insulin resistance, and endothelial dysfunction in Korean healthy adults
    115. Relation of Visceral Adiposity to circulating natriuretic peptides in ambulatory individuals
    116. Are general obesity and Visceral Adiposity in men linked to reduced bone mineral content resulting from normal ageing? A population‐based study
    117. Association of abdominal Visceral Adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients
    118. Waist circumference measurement site does not affect relationships with Visceral Adiposity and cardiometabolic risk factors in children
    119. Visceral Adiposity index is associated with pre-diabetes and type 2 diabetes mellitus in Chinese adults aged 20-50
    120. Visceral Adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large …
    121. Olanzapine-induced weight gain and increased Visceral Adiposity is blocked by melatonin replacement therapy in rats
    122. Visceral Adiposity and left ventricular remodeling: the Multi-Ethnic Study of Atherosclerosis
    123. Prognostic significance of the complex” Visceral Adiposity index” vs. simple anthropometric measures: Tehran lipid and glucose study
    124. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and Visceral Adiposity
    125. Association of serum retinol-binding protein 4 and Visceral Adiposity in Chinese subjects with and without type 2 diabetes
    126. Dietary chickpeas reverse Visceral Adiposity, dyslipidaemia and insulin resistance in rats induced by a chronic high-fat diet
    127. Impact of body mass index and Visceral Adiposity on outcomes in colorectal cancer
    128. Aerobic plus resistance training was more effective in improving the Visceral Adiposity, metabolic profile and inflammatory markers than aerobic training in obese …
    129. Chronic maternal dietary chromium restriction modulates Visceral Adiposity: probable underlying mechanisms
    130. Visceral Adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease
    131. Low cardiorespiratory fitness levels and elevated blood pressure: what is the contribution of Visceral Adiposity?
    132. Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, Visceral Adiposity, and hypoadiponectinemia in …
    133. Visceral Adiposity and colorectal adenomas: dose-response meta-analysis of observational studies
    134. Visceral Adiposity is a risk factor for poor prognosis in colorectal cancer patients receiving adjuvant chemotherapy
    135. Peripheral, but not central, administration of adiponectin reduces Visceral Adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese …
    136. Significant correlation between Visceral Adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects
    137. Indirect measure of Visceral Adiposity ‘A Body Shape Index'(ABSI) is associated with arterial stiffness in patients with type 2 diabetes
    138. The effects of acute hyperglycemia and hyperinsulinemia on plasma leptin levels: its relationships with body fat, Visceral Adiposity, and age in women
    139. Sleep-disordered breathing in obese adolescents is associated with Visceral Adiposity and markers of insulin resistance
    140. A thyroid hormone receptor α gene mutation (P398H) is associated with Visceral Adiposity and impaired catecholamine-stimulated lipolysis in mice
    141. Stop feeding cancer: pro-inflammatory role of Visceral Adiposity in liver cancer
    142. Changes in both global diet quality and physical activity level synergistically reduce Visceral Adiposity in men with features of metabolic syndrome
    143. Improved insulin sensitivity despite increased Visceral Adiposity in mice deficient for the immune cell transcription factor T-bet
    144. Sagittal abdominal diameter and Visceral Adiposity
    145. Visceral Adiposity, increased adipocyte lipolysis, and metabolic dysfunction in obese postmenopausal women
    146. Hyperleptinemia, Visceral Adiposity, and decreased glucose tolerance in mice with a targeted disruption of the histidine decarboxylase gene
    147. The relationship between “food addiction” and Visceral Adiposity in young females
    148. Functional variation in the androgen-receptor gene is associated with Visceral Adiposity and blood pressure in male adolescents
    149. FFAs and QT intervals in obese women with Visceral Adiposity: effects of sustained weight loss over 1 year
    150. Visceral Adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1
    151. Visceral Adiposity and risk of coronary heart disease in relatively lean Chinese adults
    152. Dietary predictors of Visceral Adiposity in overweight young adults
    153. Dietary determinants of hepatic steatosis and Visceral Adiposity in overweight and obese youth at risk of type 2 diabetes
    154. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced Visceral Adiposity, and improved insulin sensitivity in genetically obese Zucker rats
    155. Visceral Adiposity and endothelial lipase
    156. Garcinia cambogia extract ameliorates Visceral Adiposity in C57BL/6J mice fed on a high-fat diet
    157. Lipid accumulation product and Visceral Adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype
    158. Serum levels of pigment epithelium‐derived factor (PEDF) are positively associated with Visceral Adiposity in Japanese patients with type 2 diabetes
    159. Insulin resistance, beta cell dysfunction and Visceral Adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family …
    160. Visceral Adiposity, fasting plasma insulin, and blood pressure in Japanese-Americans
    161. Constant light induces alterations in melatonin levels, food intake, feed efficiency, Visceral Adiposity, and circadian rhythms in rats
    162. Visceral Adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome
    163. Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with Visceral Adiposity
    164. Hepatic steatosis rather than Visceral Adiposity is more closely associated with insulin resistance in the early stage of obesity
    165. High-fructose diet leads to Visceral Adiposity and hypothalamic leptin resistance in male rats—do glucocorticoids play a role?
    166. Unique profile of chicken adiponectin, a predominantly heavy molecular weight multimer, and relationship to Visceral Adiposity
    167. Visceral Adiposity in persons with chronic spinal cord injury determined by dual energy X‐ray absorptiometry
    168. Visceral Adiposity index and lipid accumulation product index: two alternate body indices to identify chronic kidney disease among the rural population in Northeast …
    169. Measures of body Adiposity and Visceral Adiposity index as predictors of metabolic syndrome among Thai women with PCOS
    170. Short‐term melatonin consumption protects the heart of obese rats independent of body weight change and Visceral Adiposity
    171. Visceral Adiposity and left ventricular mass and function in patients with aortic stenosis: the PROGRESSA study
    172. Increased Visceral Adiposity is associated with coronary artery calcification in male patients with chronic kidney disease
    173. The Visceral Adiposity index in comparison with easily measurable anthropometric markers did not improve prediction of diabetes
    174. Effect of orlistat alone or in combination with Garcinia cambogia on Visceral Adiposity index in obese patients
    175. Significant associations of age, menopausal status and lifestyle factors with Visceral Adiposity in African-American and European-American women
    176. Combination therapy with naltrexone and bupropion for obesity reduces total and Visceral Adiposity
    177. The relationship between Visceral Adiposity and left ventricular diastolic function: results from the Baltimore Longitudinal Study of Aging
    178. Relationships between exercise-induced reductions in thigh intermuscular adipose tissue, changes in lipoprotein particle size, and Visceral Adiposity
    179. Impact of Visceral Adiposity measured by abdominal computed tomography on pulmonary function
    180. Impact of increased Visceral Adiposity with normal weight on the progression of arterial stiffness in Japanese patients with type 2 diabetes
    181. Visceral Adiposity and anthropometric indicators as screening tools of metabolic syndrome among low income rural adults in Xinjiang
    182. Visceral Adiposity and cardiometabolic risks: epidemic of abdominal obesity in North America
    183. The Visceral Adiposity index: Relationship with cardiometabolic risk factors in obese and overweight postmenopausal women–A MONET group study
    184. Anthropometric predictors of Visceral Adiposity in normal‐weight and obese adolescents
    185. Higher intake of PUFAs is associated with lower total and Visceral Adiposity and higher lean mass in a racially diverse sample of children
    186. Contribution of Visceral Adiposity to the exaggerated postprandial lipemia of men with impaired glucose tolerance
    187. Applicability of Visceral Adiposity index in predicting metabolic syndrome in adults with obstructive sleep apnea: a cross-sectional study
    188. Increased Visceral Adiposity and cortisol to cortisone ratio in adults with congenital lifetime isolated GH deficiency
    189. Intramyocellular lipid is associated with Visceral Adiposity, markers of insulin resistance, and cardiovascular risk in prepubertal children: the EPOCH study
    190. Age-related changes in basal substrate oxidation and Visceral Adiposity and their association with metabolic syndrome
    191. Visceral Adiposity index and insulin secretion and action in first‐degree relatives of subjects with type 2 diabetes
    192. Eight weeks of a combination of high intensity interval training and conventional training reduce Visceral Adiposity and improve physical fitness: a group-based …
    193. Constitutive adipocyte mTORC1 activation enhances mitochondrial activity and reduces Visceral Adiposity in mice
    194. The relationship between Visceral Adiposity and the risk of erosive esophagitis in severely obese Chinese patients
    195. Visceral Adiposity, insulin resistance, and type 2 diabetes
    196. Decreased Visceral Adiposity accounts for leptin effect on hepatic but not peripheral insulin action
    197. Visceral Adiposity index score indicated the severity of coronary heart disease in Chinese adults
    198. Visceral Adiposity in the first half of pregnancy predicts newborn weight among adolescent mothers
    199. Association between birth weight and insulin sensitivity in healthy young men in Korea: role of Visceral Adiposity
    200. … lower sex hormone binding globulin and higher dehydroepiandrosterone sulfate levels and aggravate their Visceral Adiposity and hypoadiponectinemia between six …
    201. Association of dietary factors with abdominal subcutaneous and Visceral Adiposity in Japanese men
    202. Comparative relation of general, central, and Visceral Adiposity measures for coronary artery calcium in subjects without previous coronary events
    203. Left ventricular structure and function in obese adolescents: relations to cardiovascular fitness, percent body fat, and Visceral Adiposity, and effects of physical training
    204. Association between Visceral Adiposity and colorectal polyps on CT colonography
    205. Visceral Adiposity, not abdominal subcutaneous fat area, is associated with high blood pressure in Japanese men: the Ohtori study
    206. Combined impact of cardiorespiratory fitness and Visceral Adiposity on metabolic syndrome in overweight and obese adults in Korea
    207. Oleuropein attenuates Visceral Adiposity in high‐fat diet‐induced obese mice through the modulation of WNT10b‐and galanin‐mediated signalings
    208. Aerobic exercise attenuates the loss of skeletal muscle during energy restriction in adults with Visceral Adiposity
    209. Visceral Adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension
    210. Low birth weight male guinea pig offspring display increased Visceral Adiposity in early adulthood
    211. Contributions of cardiorespiratory fitness and Visceral Adiposity to six-year changes in cardiometabolic risk markers in apparently healthy men and women
    212. Visceral Adiposity and subclinical coronary artery disease in elderly adults: Rancho Bernardo Study
    213. Volume-dependent effect of supervised exercise training on fatty liver and Visceral Adiposity index in subjects with type 2 diabetes The Italian Diabetes Exercise Study …
    214. … Insulin resistance, in obese and non obese, diabetics and non diabetics: A cross sectional observational study.(Mysore Visceral Adiposity in Diabetes Study)
    215. Maternal X chromosome, Visceral Adiposity, and lipid profile
    216. PDE5 inhibition ameliorates Visceral Adiposity targeting the miR-22/SIRT1 pathway: evidence from the CECSID trial
    217. Sedentariness and increased Visceral Adiposity in adult perinatally iron-deficient rats
    218. Role of the insulin-like growth factor 1 axis and Visceral Adiposity in oesophageal adenocarcinoma
    219. Epicardial adipose tissue is related to carotid intima-media thickness and Visceral Adiposity in HIV-infected patients with highly active antiretroviral therapy-associated …
    220. Insulin, C-peptide, and leptin concentrations predict increased Visceral Adiposity at 5-and 10-year follow-ups in nondiabetic Japanese Americans
    221. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients
    222. Visceral Adiposity is preferentially associated with vascular stiffness rather than thickness in men with type 2 diabetes
    223. Visceral Adiposity index and prognosis among patients with ischemic heart failure
    224. Influence of high-normal serum TSH levels on major cardiovascular risk factors and Visceral Adiposity Index in euthyroid type 2 diabetic subjects
    225. The heme oxygenase system suppresses perirenal Visceral Adiposity, abates renal inflammation and ameliorates diabetic nephropathy in Zucker diabetic fatty …
    226. Visceral Adiposity, androgens, and plasma lipids in obese men
    227. Visceral Adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome
    228. Visceral Adiposity is not associated with abdominal aortic aneurysm presence and growth
    229. Visceral Adiposity is associated with cytokines and decrease in lung function in women with persistent asthma
    230. Visceral Adiposity is associated with SIRT1 expression in peripheral blood mononuclear cells: a pilot study
    231. Apolipoprotein A‐II polymorphism and Visceral Adiposity in African‐American and white women
    232. Autocrine function of aldehyde dehydrogenase 1 as a determinant of diet-and sex-specific differences in Visceral Adiposity
    233. Does Visceral Adiposity index signify early metabolic risk in children and adolescents?: association with insulin resistance, adipokines, and subclinical …
    234. Nontraditional risk factors for cardiovascular disease and Visceral Adiposity index among different body size phenotypes
    235. Reduction in Visceral Adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin
    236. Visceral Adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients
    237. The contribution of Visceral Adiposity and mid‐thigh fat‐rich muscle to the metabolic profile in postmenopausal women
    238. Visceral Adiposity, fasting plasma insulin, and lipid and lipoprotein levels in Japanese Americans.
    239. Changes in Visceral Adiposity and serum cholesterol with a novel viscous polysaccharide in Japanese adults with abdominal obesity
    240. Treatment with a SOD mimetic reduces Visceral Adiposity, adipocyte death, and adipose tissue inflammation in high fat‐fed mice
    241. Increased risk of subclinical atherosclerosis associated with high Visceral Adiposity index in apparently healthy Korean adults: the Kangbuk Samsung Health Study
    242. Contribution of Visceral Adiposity and insulin resistance to metabolic risk factors in Japanese men
    243. Novel genes of Visceral Adiposity: identification of mouse and human mesenteric estrogen-dependent adipose (MEDA)-4 gene and its adipogenic function
    244. Troglitazone prevents the rise in Visceral Adiposity and improves fatty liver associated with sulfonylurea therapy—a randomized controlled trial
    245. Brown fat lipoatrophy and increased Visceral Adiposity through a concerted adipocytokines overexpression induces vascular insulin resistance and dysfunction
    246. Plasma soluble tumour necrosis factor‐α receptor 2 is elevated in obesity: specific contribution of Visceral Adiposity
    247. Association of serum C1q/TNF-Related Protein-9 (CTRP9) concentration with Visceral Adiposity and metabolic syndrome in humans
    248. Liver fat, Visceral Adiposity, and sleep disturbances contribute to the development of insulin resistance and glucose intolerance in nondiabetic dialysis patients
    249. Insulin resistance and metabolic syndrome are related to non-alcoholic fatty liver disease, but not Visceral Adiposity index, in severely obese patients
    250. Insulin resistance but not Visceral Adiposity index is associated with liver fibrosis in nondiabetic subjects with nonalcoholic fatty liver disease
    251. Alteration of the growth hormone axis, Visceral fat dysfunction, and early cardiometabolic risk in adults: the role of the Visceral Adiposity index
    252. Apolipoprotein B/A1 ratio is associated with free androgen index and Visceral Adiposity and may be an indicator of metabolic syndrome in male children and …
    253. … in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, Visceral Adiposity, insulin sensitivity, and …
    254. An acylic polyisoprenoid derivative, geranylgeranylacetone protects against Visceral Adiposity and insulin resistance in high-fat-fed mice
    255. Visceral Adiposity is associated with an increased risk of functional dyspepsia
    256. Is there a role for Visceral Adiposity in inducing type 2 diabetes remission in severely obese patients following biliopancreatic diversion with duodenal switch surgery?
    257. Visceral Adiposity is associated with increased lipid oxidation in obese, postmenopausal women
    258. Objectively quantified physical activity and sedentary behavior in predicting Visceral Adiposity and liver fat
    259. Mild electrical stimulation with heat shock reduces Visceral Adiposity and improves metabolic abnormalities in subjects with metabolic syndrome or type 2 …
    260. Common variants near melanocortin 4 receptor are associated with general and Visceral Adiposity in European-and African-American youth
    261. Gonadal failure is associated with Visceral Adiposity in myotonic dystrophies
    262. Late gestation over‐and undernutrition predispose for Visceral Adiposity in response to a post‐natal obesogenic diet, but with differential impacts on glucose–insulin …
    263. Low insulin secretion and high fasting insulin and C-peptide levels predict increased Visceral Adiposity: 5-year follow-up among initially nondiabetic Japanese …
    264. Association of nonalcoholic fatty liver disease with Visceral Adiposity but not coronary artery calcification in the elderly
    265. Association of dietary proportions of macronutrients with Visceral Adiposity index: non-substitution and iso-energetic substitution models in a prospective study
    266. The impact of blood pressure and Visceral Adiposity on the association of serum uric acid with albuminuria in adults without full metabolic syndrome
    267. Hepatic fat content-independent association of the serum level of gamma-glutamyltransferase with Visceral Adiposity, but not subcutaneous Adiposity
    268. Visceral Adiposity is associated with altered myocardial glucose uptake measured by 18 FDG-PET in 346 subjects with normal glucose tolerance, prediabetes …
    269. Metformin therapy to reduce weight gain and Visceral Adiposity in children and adolescents with neurogenic or myogenic motor deficit
    270. Causes and consequences of human variation in Visceral Adiposity
    271. Excess Visceral Adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma
    272. Dietary vitamin A and Visceral Adiposity: a modulating role of the retinol-binding protein 4 gene
    273. Visceral Adiposity index, hypertriglyceridemic waist phenotype and chronic kidney disease in a southern Chinese population: a cross-sectional study
    274. Reduction of Visceral Adiposity after operation in a subject with insulinoma
    275. Visceral Adiposity and skeletal muscle mass are independently and synergistically associated with left ventricular structure and function: the Korean Genome and …
    276. Reversal of Visceral Adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant
    277. Hyperhomocysteinemia is associated with Visceral Adiposity in Japanese patients with type 2 diabetes mellitus
    278. Visceral Adiposity and subclinical atherosclerosis in healthy young men
    279. Visceral Adiposity in the first half of pregnancy in association with glucose, lipid and insulin profiles in later pregnancy: a cohort study
    280. Association of breastfeeding with postmenopausal Visceral Adiposity among three racial/ethnic groups
    281. Correlation of renin angiotensin and aldosterone system activity with subcutaneous and Visceral Adiposity: the framingham heart study
    282. Visceral Adiposity is not associated with inflammatory markers in trauma patients
    283. A pilot study of telmisartan for Visceral Adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial
    284. Impaired growth hormone secretion correlates with Visceral Adiposity in highly active antiretroviral treated HIV-infected adolescents
    285. Is Visceral Adiposity a significant correlate of subcutaneous adipose cell lipolysis in men?
    286. Higher Visceral Adiposity is associated with an enhanced early thermogenic response to carbohydrate-rich food
    287. Visceral Adiposity is a predictor of parathyroid hormone levels in healthy adults
    288. Prunus mume and Lithospermum erythrorhizon extracts synergistically prevent Visceral Adiposity by improving energy metabolism through potentiating …
    289. Increased Visceral Adiposity with normal weight is associated with the prevalence of non‐alcoholic fatty liver disease in Japanese patients with type 2 diabetes
    290. Cut-off values of Visceral Adiposity to predict NAFLD in Brazilian obese adolescents
    291. Flavonoid-rich Chardonnay grape seed flour supplementation ameliorates diet-induced Visceral Adiposity, insulin resistance, and glucose intolerance via altered …
    292. Brain-derived neurotrophic factor in VMH as the causal factor for and therapeutic tool to treat Visceral Adiposity and hyperleptinemia in type 2 diabetic Goto …
    293. … of Visceral Adiposity index with chronic kidney disease in the People’s Republic of China: to rediscover the new clinical potential of an old indicator for Visceral …
    294. Carotid atherosclerosis mediated by Visceral Adiposity and adipocytokines in type 2 diabetic subjects
    295. Visceral Adiposity in young patients with coronary artery disease—a case control study
    296. Tonsil-derived mesenchymal stem cells promote bone mineralization and reduce marrow and Visceral Adiposity in a mouse model of senile osteoporosis
    297. Long-term risperidone treatment induces Visceral Adiposity associated with hepatic steatosis in mice: a magnetic resonance approach
    298. Sleep and birthweight predict Visceral Adiposity in overweight/obese children
    299. Normalization of Visceral Adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification …
    300. Novel gender-specific Visceral Adiposity index for Mexican pediatric population
    301. The efficiency of cavitation ultrasound therapy on Visceral Adiposity in perimenpausal women
    302. Distinctive inhibitory mechanisms of age and relative Visceral Adiposity on growth hormone secretion in pre-and postmenopausal women studied under a …
    303. Visceral Adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia
    304. Proteomics and genomics: A hypothesis‐free approach to the study of the role of Visceral Adiposity in the pathogenesis of the polycystic ovary syndrome
    305. … effects of calcitriol on hypertension, glucose intolerance, impairment of endothelium-dependent vascular relaxation, and Visceral Adiposity in fructose-fed …
    306. The association of Visceral Adiposity with cardiovascular events in patients with peripheral artery disease
    307. Visceral Adiposity would be expected to predict incident diabetes better in women than men
    308. Visceral Adiposity Index and pattern of dyslipidaemia at different stages of glucose intolerance—A study from India
    309. Reduction in Visceral Adiposity is highly related to improvement in vascular endothelial dysfunction among obese women: an assessment of endothelial …
    310. Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and Visceral Adiposity
    311. Pregnancy in obese mice protects selectively against Visceral Adiposity and is associated with increased adipocyte estrogen signalling
    312. Racial differences between African-American and white women in insulin resistance and Visceral Adiposity are associated with differences in apoCIII …
    313. A Visceral Adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome
    314. Whole-body vibration partially reverses aging-induced increases in Visceral Adiposity and hepatic lipid storage in mice
    315. Low‐calorie diet induced weight loss may alter regulatory hormones and contribute to rebound Visceral Adiposity in obese persons with a family history of type‐2 …
    316. Multidisciplinary treatment reduces Visceral Adiposity tissue, leptin, ghrelin and the prevalence of non-alcoholic fat liver disease (NAFLD) in obese adolescents
    317. Subcutaneous adipose tissue insulin resistance is associated with Visceral Adiposity in postmenopausal women
    318. Can increased Visceral Adiposity without body weight changes accelerate carotid atherosclerosis in South Korean participants with type 2 diabetes?
    319. Visceral Adiposity in Saudi females and its relationship to diet and serum adipocytokine levels
    320. … PPARγ agonist, induces the expression of thermogenesis-related genes in brown fat and Visceral white fat and decreases Visceral Adiposity in obese and …
    321. Possibility radiological methods in diagnostics of Visceral Adiposity
    322. Glucose tolerance is affected by Visceral Adiposity and sex, but not birth weight, in Yucatan miniature pigs
    323. Effects of Visceral fat accumulation awareness on a web-based weight-loss program: Japanese study of Visceral Adiposity and lifestyle information—Utilization …
    324. Renal manifestations and Visceral Adiposity in apparently healthy Korean women
    325. Visceral Adiposity and its association with serum lipids in female obese teenagers
    326. Is Visceral Adiposity a modifier for the impact of blood pressure on arterial stiffness and albuminuria in patients with type 2 diabetes?
    327. Abdominal Visceral Adiposity influences CD4+ T cell cytokine production in pregnancy
    328. Changes in adiponectin and inflammatory genes in response to hormonal imbalances in female mice and exacerbation of depot selective Visceral Adiposity by high-fat …
    329. Influence of the body mass and Visceral Adiposity on glucose metabolism in obese women with Pro12Pro genotype in PPARgamma2 gene
    330. Beyond central Adiposity: liver fat and Visceral fat area are associated with metabolic syndrome in morbidly obese patients
    331. Visceral, subcutaneous abdominal Adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose …
    332. Utilizing quantitative measures of Visceral Adiposity in evaluating trauma patient outcomes
    333. Poor sleep quality potentiates stress-induced cytokine reactivity in postmenopausal women with high Visceral abdominal Adiposity
    334. Hepatocyte growth factor and interferon‐γ inducible protein‐10 are related to Visceral Adiposity
    335. Recombinant human growth hormone therapy in HIV-associated wasting and Visceral Adiposity
    336. Visceral Adiposity after tibolone use
    337. Maternal tobacco smoke increased Visceral Adiposity and serum corticosterone levels in adult male rat offspring
    338. The current version of the Visceral Adiposity index is not suitable for application in pediatric populations: comments on the article by Al-Daghri et al.
    339. A short-duration restrictive diet reduces Visceral Adiposity in the morbidly obese surgical patient
    340. Sex differences in the associations of Visceral Adiposity, homeostatic model assessment of insulin resistance, and body mass index with lipoprotein subclass analysis …
    341. Circulating irisin levels reflect Visceral Adiposity in non-diabetic patients undergoing hemodialysis
    342. Comment on: Padmavathi et al.(2010) Chronic Maternal Dietary Chromium Restriction Modulates Visceral Adiposity: Probable Underlying Mechanisms. Diabetes; 59 …
    343. … region of rat chromosome 8 in SHR-derived polydactylous congenic substrain affects muscle-specific insulin resistance, dyslipidaemia and Visceral Adiposity
    344. Influence of Visceral Adiposity on cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus
    345. … synthase kinase-3β and hexose-6-phosphate dehydrogenase expression in adipose tissue may contribute to glucocorticoid-induced mouse Visceral Adiposity
    346. Central Nervous System Lipocalin‐Type Prostaglandin D2‐Synthase is Correlated with Orexigenic Neuropeptides, Visceral Adiposity and Markers of the …
    347. Cardiac Visceral Adiposity and right ventricle apex remodelling-Locus minoris resistentiae
    348. Influence of Visceral Adiposity on ghrelin secretion and expression in rats during fasting
    349. Novel relationships of age, Visceral Adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and …
    350. Application of Visceral Adiposity Index and Anthropometry to Identify Preclinical Atherosclerosis in Menopausal Status Women.
    351. Insulin sensitivity and secretion in youth onset type 2 diabetes with and without Visceral Adiposity
    352. Hypovitaminosis D is associated with Visceral Adiposity, high levels of low-density lipoprotein and triglycerides in alternating shift workers
    353. Association of Visceral and subcutaneous Adiposity with kidney function
    354. Visceral Adiposity and apolipoprotein C-III in apolipoprotein B-containing lipoproteins are independent predictors in determining atherogenic lipid profiles
    355. Noble rats display decreased weight gain and Visceral Adiposity via lifelong exposure to an isoflavone-rich diet
    356. Interventions for Visceral Adiposity associated with human immunodeficiency virus: application of a method for assessing efficacy
    357. Prevention of diabetes by fenofibrate in OLETF rats: hepatic mechanism for reducing Visceral Adiposity
    358. Body mass index, waist circumference, Visceral Adiposity, and cardiometabolic risk profile
    359. Computerized tomography measurement of Visceral Adiposity predicts plasma adiponectin levels and metastatic disease in patients with clear cell renal cell …
    360. Usefulness of the Visceral Adiposity index in different populations
    361. Visceral/epicardial Adiposity in nonobese and apparently healthy young adults: association with the cardiometabolic profile
    362. Relationship of Visceral and subcutaneous Adiposity with renal function in people with type 2 diabetes mellitus
    363. Association of Visceral Adiposity with urinary albumin excretion in type 2 diabetics
    364. The associations between various ectopic Visceral Adiposity and body surface electrocardiographic alterations: potential differences between local and …
    365. Adipose tissue gene expression profiling reveals distinct molecular pathways that define Visceral Adiposity in o…
    366. Visceral Adiposity and inflammation
    367. Computed tomography for assessment of Visceral Adiposity
    368. Comparison of Visceral Adiposity Index with Other Indices of Adiposity in Patients with Acute Myocardial Infarction
    369. The frequency of fish-eating could negatively associate with Visceral Adiposity in those who eat moderately
    370. Relationship of Visceral Adiposity with plasma adiponectin concentration: effect of weight loss
    371. Physiologic effects of GHRH in patients with HIV lipodystrophy: a model of acquired Visceral Adiposity
    372. Relationship between Visceral Adiposity and plasma adiponectin concentration: Effect of weight loss
    373. Visceral Adiposity index (vai), as the best predictor of insulin resistance and metablis syndrome in the women with polycystic ovary syndrome
    374. Role of Micro RNA-205 in Promoting Visceral Adiposity of NZ10 Mice with Polygenic Susceptibility for Type 2 Diabetes
    375. Visceral and subcutaneous Adiposity measurements in adults: influence of measurement site
    376. Gender Difference in Inflammatory Markers: What is the Contribution of Visceral Adiposity?
    377. The relationship between lipid accumulation product, Visceral Adiposity index and high-sensitivity C-reactive protein in healthy adults
    378. Hepatic steatosis, Visceral Adiposity, insulin resistance, adiponectin, and inflammation
    379. Comparison of Visceral Adiposity and obesity parameters in Caucasian and Hispanic adults
    380. Visceral and subcutaneous Adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?
    381. Prediction of total and Visceral fat contents using anthropometric measures of Adiposity in women
    382. Lack of ST2 enhances high-fat diet-induced Visceral Adiposity and inflammation in BALB/c mice
    383. Visceral Adiposity and The Relationship Between Vitamin D and Adiponectin
    384. … a weight loss support web system on Visceral fat loss in a workplace setting: insights from a JVALUE2 (Japanese study of Visceral Adiposity and lifestyle information; …
    385. Association of Serum Retinol Binding Protein 4 and Visceral Adiposity in Chinese Diabetes and Non-Diabetes Subjects.
    386. Accuracy parameters as indicators of anthropometric Adiposity Visceral scheduled for two-dimensional equation
    387. Pubertal metformin therapy to reduce total, Visceral, and hepatic Adiposity
    388. Response to Comment on: Padmavathi et al.(2010) Chronic Maternal Dietary Chromium Restriction Modulates Visceral Adiposity: Probable Underlying Mechanisms …
    389. Age-related differences in inflammatory markers: Contribution of Visceral Adiposity
    390. AB0579 The relationship between Visceral Adiposity index and disability function in a cohort of psoriatic arthritis patients
    391. Increased Visceral Adiposity index in patients with polycystic ovary syndrome; relationship between inflammation, insulin resistance and hyperandrogenity
    392. Predicting total, abdominal, Visceral and hepatic Adiposity with circulating biomarkers in Caucasian and Japanese American women
    393. Visceral and not subcutaneous abdominal Adiposity reduction drives the benefits of a 1‐year lifestyle modification program
    394. Association between Visceral Adiposity, BMI, and clinical outcomes in postmenopausal women with operable breast cancer.
    395. Association between Visceral and subcutaneous Adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma
    396. Measurements of Visceral Adiposity, type-2 diabetes and risk for cardiovascular disease among Brazilian men and women
    397. The Sodium Glucose Co-transporter 2 Inhibitor (SGLT2i) Empagliflozin reduces weight and markers of Visceral Adiposity (VA) in type 2 diabetes (T2D) in short-and …
    398. Dietary fructose-related Adiposity and glucocorticoid receptor function in Visceral adipose tissue of female rats
    399. Prospective evidence that HIV lipoatrophy and Visceral Adiposity are partially independent processes
    400. Relationship of Visceral Adiposity index with serum aminotransferase and nonalcoholic fatty liver disease in patients with sleep apnea
    401. Visceral Adiposity cut-off points to indicate risk factor to develop the nonalcoholic fatty liver disease in Brazilian and Italian obese adolescents
    402. Effects of weight loss on Visceral Adiposity and metabolic adaptations in diabetic versus non-diabetic women
    403. Association of Visceral Adiposity with hypertension, dyslipidemia, and type 2 diabetes: a cross-sectional study among Japanese men and women
    404. Markers of Visceral Adiposity for Dementia Risk Assessment. The Epicardial Adipose Tissue (EAT) Thickness.
    405. Visceral Adiposity is Associated with Increased Risk of Anastomotic Leakage Following Surgery for Colorectal Cancer.
    406. Greater consumption of polyunsaturated fatty acids are related to increased lean mass and decreased Visceral Adiposity in a multi-ethnic sample of children
    407. Secretagogue type, sex-steroid milieu, and abdominal Visceral Adiposity individually determine secretagogue-stimulated cortisol secretion
    408. Sex differences in the associations of Visceral Adiposity, HOMA-IR, and BMI with lipoprotein subclass analysis in obese adolescents
    409. 665 Impact of Abdominal Visceral Adiposity on Left Ventricular Hypertrophy and Systolic Dysfunction in Patients With Aortic Stenosis-Results From the PROGRESSA …
    410. Grape seed extract decreases Visceral Adiposity and impairs the pro-tumorigenic adipose tissue secretions affecting colorectal cancer growth and progression
    411. Insulin Resistance, Visceral Adiposity Index and TyG Index in Genotype-4 Chronic HCV Patients and Their Relation to Hepatic Histopathology
    412. Ethnic and sex differences in body fat and Visceral and subcutaneous Adiposity in children and adolescents
    413. Association of Visceral Adiposity with increased intrarenal artery resistive index in HIV-1-infected patients receiving highly active antiretroviral therapy
    414. Anthropometric markers of Adiposity and Visceral Adiposity index (VAI) in patients with OSA
    415. Automated separation of Visceral and subcutaneous Adiposity in in vivo microcomputed tomographies of mice
    416. PP. 16.04: Visceral Adiposity INDEX AND CARDIOVASCULAR RISK IN THE ELDERLY
    417. Is BMI Good Enough to Measure Visceral Adiposity?
    418. What arises from the decrease of Visceral Adiposity in Japanese diabetic patients with Visceral fat accumulation?
    419. Psychosocial predictors of Visceral Adiposity
    420. Is Visceral Adiposity predictor of aortic diseases?
    421. Gender differences in the association of Visceral and subcutaneous Adiposity with adiponectin in African Americans: the Jackson Heart Study
    422. Association between NT-proBNP and Visceral Adiposity
    423. A Thyroid Hormone Receptor Gene Mutation(P 398 H) Is Associated with Visceral Adiposity and Impaired Catecholamine-stimulated Lipolysis in Mice
    424. Gator Circle: A new noninvasive method for evaluating Visceral Adiposity
    425. S-281: Increased risk for subclinical atherosclerosis in subjects with high Visceral Adiposity index
    426. Genetic determinants of Visceral Adiposity in Type 2 Diabetes Mellitus
    427. Assessment of Visceral Adiposity in rats submitted to high fat diet
    428. Sleep apnoea and Visceral Adiposity in middle-aged male and female
    429. Visceral Adiposity and Controlling Body Weight through Diet and Exercise
    430. HIGH Visceral Adiposity INDEX (VAI) SCORE BEFORE AND AFTER TREATMENT IN YOUNGH HIV-POSITIVE PATIENTS
    431. Visceral Adiposity associated with increased risk of death from ovarian cancer
    432. Does Visceral Adiposity Influence the Standard of Care Response for Hepatitis C Patients?
    433. Modeling Body Composition with Special Attention to Visceral Adiposity
    434. The use of Visceral Adiposity Variables in the evaluation of Obstructive Sleep Apnea: evidence from a large cross-sectional study
    435. IS Visceral Adiposity INDEX (VAI) RELATED TO PROSTATE CANCER DETECTED BY BIOPSY?
    436. Abstract MP028: Physical Activity Relates to Lower Visceral Adiposity in Children and Adolescents
    437. Aplicabilidad del Visceral Adiposity index (VAI) en la predicción de componentes del síndrome metabólico en adultos jóvenes
    438. Metabolic Control by Inflammation and Immunity: Inflammation mediates the association between Visceral Adiposity and obstructive sleep apnea in …
    439. Impact of Visceral Adiposity on blood pressure in normotensive people: a study among health staff
    440. Impact of Visceral Adiposity on outcomes from hepatocellular carcinoma following liver transplantation
    441. Can increased Visceral Adiposity without body weight changes accelerate carotid
    442. The association between BMI change and subcutaneous and Visceral Adiposity in adulthood: the Kangwha study
    443. Susceptibility variants for waist size in relation to abdominal, Visceral, and hepatic Adiposity in postmenopausal women
    444. Detection of Visceral Adiposity by ultrasonography and its relation to insulin resistance in HCV patients
    445. Perinatal iron deficiency results in increased Visceral Adiposity in male Wistar rats
    446. Visceral Adiposity and its association with serum lipids in female obese teenagers Adiposidad Visceral y su asociación con lípidos séricos e insulinemia en …
    447. THERE IS DISCORDANCE BETWEEN ARTERIAL STIFFNESS AND PERIPHERAL WAVE REFLECTIONS IN HYPERTENSIVES WITH Visceral Adiposity: PP …
    448. Evaluation of metabolic parameters in patients with craniopharyngiomas using Visceral Adiposity index
    449. Physical Activity Intensity and Visceral Adiposity in Youth: A Randomized Controlled Trial
    450. Visceral Adiposity: DISCORDANCE BETWEEN ARTERIAL STIFFNESS AND PERIPHERAL WAVE REFLECTIONS: PP. 34.361
    451. GW25-e1085 Predictive value of “Visceral Adiposity Index” for Type 2 Diabetes mellitus: A 15-year prospective cohort study
    452. Influence of Visceral Adiposity on cardiovascular autonomic function in type 2 diabetes
    453. Applicability of Visceral Adiposity Index in Predicting Metabolic Syndrome in Adults With Obstructive Sleep Apnea
    454. Effects of diet macronutrient composition on Visceral Adiposity during weight maintenance
    455. Exercise for reducing Visceral Adiposity: Aerobic or resistance training?
    456. Detection of Visceral Adiposity by Ultrasonography and its relation to insulin resistance in HCV patients
    457. Visceral Adiposity Index (VAI) as a simple indicator of “adipose tissue dysfunction” in patients with type 2 diabetes.
    458. Retention of sedentary obese Visceral white adipose tissue phenotype with intermittent physical activity despite reduced Adiposity
    459. Erratum for Nazare et al.“Usefulness of Measuring Both Body Mass Index and Waist Circumference for the Estimation of Visceral Adiposity and Related
    460. Decreased Visceral Adiposity Accounts for Leptin’s Effect on Hepatic but not Peripheral Insulin Action
    461. Risk of NASH and severe fibrosis in patients with NAFLD and low Visceral Adiposity
    462. Visceral Adiposity & Insulin Impairment & Dementia/Alzheimer’s
    463. Visceral Adiposity, Liver Fat, and Atherogenic Dyslipidemia
    464. Adiposity and bone: the influence of subcutaneous versus Visceral fat and insulin resistance
    465. Visceral Adiposity and Leptin Are Independently Associated with CRP in Korean Type 2 Diabetic Patients.
    466. Metabolite Profiles Associated With Variation in Visceral Adiposity: The Multi-Ethnic Study of Atherosclerosis
    467. Visceral Adiposity Index and Serum 25-OH Vitamin D: Insights from the NHANES-III
    468. Abdominal Visceral Adiposity measured by ultrasonography and risk of metabolic syndrome and its components: identification of predictive cut-off of risk
    469. [PP. 27.12] Visceral Adiposity INDEX IS ASSOCIATED WITH NOCTURNAL HYPERTENSION BUT NOT NON-DIPPING PATTERN IN UNTREATED …
    470. Excess Visceral Adiposity is Related to Left Ventricular Hypertrophy and Dysfunction in Patients with Aortic Stenosis-Results from the PROGRESSA Study
    471. Visceral Adiposity is Associated with Persistently High and Less Variable Blood Pressure: Results From the Dallas Heart Study
    472. Testosterone and dehydroepiandrosterone deficiency, general Adiposity and Visceral obesity during normal male aging
    473. When Essential Hypertension is Combined With Visceral Adiposity There is Discordance Between Arterial Stiffness and Peripheral Wave Reflections
    474. Abstract P382: Visceral Adiposity is a Stronger Correlate of Plasma C-Reactive Protein Levels than Liver Fat in the INSPIRE ME IAA Study.
    475. Whole-and refined-grain intakes are differentially associated with abdominal Visceral and subcutaneous Adiposity in healthy adults: the Framingham Heart Study
    476. Abstract P222: Sex Differences in the Association of Visceral Adiposity with Lipoprotein Subclass Analysis in Obese Adolescents
    477. Cardiac and hepatic phenotype of diabetes in the presence and the absence of obesity-mechanistic role of ectopic/Visceral Adiposity
    478. Hypogonadism, insulin resistance and Visceral Adiposity in myotonic dystrophy
    479. Visceral Adiposity index as a marker of hepatic steatosis in overweight and obese premenopausal women
    480. Visceral Adiposity index-new anthropometric marker in women with polycystic ovary syndrome: preliminary reports
    481. … Lifestyle Intervention in Men with Features of the Metabolic Syndrome is Related to Improvements in Lipid Profile Independent of the Reduction in Visceral Adiposity
    482. Preeclampsia and Preterm Birth Associated With Visceral Adiposity in Early Pregnancy
    483. Impact of Visceral Adiposity on trabecular bone score in obese postmenopausal women: A cohort study
    484. BMI but not Visceral Adiposity index is related to vitamin D levels in overweight HIV-patients
    485. Lower dietary polyunsaturated to saturated fat ratio is associated with increased Visceral Adiposity
    486. Investigating the impact of subcutaneous and Visceral Adiposity on metabolism using an adipose tissue transplantation model
    487. Normalization of Visceral Adiposity is a Better Therapeutic Target Than Normalisation of Body Weight: Evidence From the Synergie Trial
    488. Visceral Adiposity index and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism
    489. Is Visceral Adiposity a Significant Correlate of Subcutaneous Adipose Cell Lipolysis in Men?
    490. EFFECTS OF CABERGOLINE TREATMENT ON METABOLIC SYNDROME AND Visceral Adiposity INDEX IN PATIENTS WITH HYPERPROLACTINEMIA.
    491. Abstract P263: Racial Differences in the Association Between Physical Activity Levels During Early Adulthood and Visceral Adiposity at Middle Age: The CARDIA …
    492. Ten Months of Exercise Improves General and Visceral Adiposity, Bone, and Fitness in Black Girls
    493. The nuclear receptor cochaperone FKBP51 is required for diet‐induced Visceral Adiposity
    494. B28 NOVEL APPROACHES TO PATIENT ASSESSMENT AND OUTCOMES OF PULMONARY REHABILITATION: Visceral Adiposity In Patients With COPD …
    495. Neck circumference is a powerful predictor of Visceral Adiposity and insulin resistance in morbid (WHO grade III) obesity
    496. Children with brain tumors have enhanced Visceral Adiposity compared to non-cancer controls: A preliminary analysis from the Canadian Study of Determinants …
    497. Evidence that Changes in Both Global Diet Quality and in Physical Activity Level Synergistically Reduce Visceral Adiposity in Men With the Metabolic Syndrome
    498. Visceral Adiposity index and metabolic profile in adult patients with congenital adrenal hyperplasia: hydrocortisone versus prednisone treatment.
    499. Viscous dietary fibers reduce Visceral Adiposity, lower oxidative stress and improve glucose control in ZDF rats
    500. Abstract P324: Abdominal Visceral Adiposity and Liver Fat in Relation to Sex-Related Differences in Cardiometabolic Risk Profile: The INSPIRE ME IAA Study
    501. LACK OF ST2 ENHANCES HIGH FAT DIET INDUCED Visceral Adiposity AND INFLAMMATION IN BALB/c MICE
    502. Greater fructose consumption is associated with cardiometabolic risk markers and Visceral Adiposity in adolescents.
    503. APPENDIX A. Diet quality is associated with lower total and Visceral Adiposity in Hispanic and non-Hispanic adolescent girls
    504. Intestinal Apolipoprotein A-IV Expression Conserves Visceral Adiposity in Mice Subjected to Cyclical Feeding and Fasting
    505. Thigh volume ratios assessed via stereovision body imaging as a predictor of Visceral Adiposity measured by magnetic resonance imaging
    506. Improvement in Hepatic Steatosis, Visceral Adiposity, and Appetite by High Dietary Protein Supplementation: 2155
    507. PP. 20.29: DISCORDANCE BETWEEN ARTERIAL STIFFNESS AND PERIPHERAL WAVE REFLECTIONS IN HYPERTENSIVES WITH Visceral Adiposity
    508. Abstract P332: Impact of Empagliflozin on Anthropometry and Markers of Visceral Adiposity in Patients With Type 2 Diabetes: Effects by Age, Sex, And Degree of …
    509. 156 INCREASED Visceral Adiposity IS ASSOCIATED WITH DECREASED GLOMERULAR FILTRATION RATE BY A MECHANISM INDEPENDENT OF …
    510. Skeletal muscle triglycerides and central Visceral Adiposity predict insulin sensitivity in lean, young, healthy subjects from two ethnic groups
    511. Dietary determinants of hepatic steatosis and Visceral Adiposity in overweight and obese youth at risk of type 2 diabetes1–3
    512. Fenofibrate Inhibits Visceral Adiposity by Inhibiting UCPs in C57BL/6J Mice Fed on a High Fat Diet
    513. Increased abdominal Visceral Adiposity is associated with unsuspected pulmonary embolism in hospitalised patients with malignant digestive tract tumours
    514. BMI, fat mass, abdominal Adiposity and Visceral fat: where is the ‘beef’?
    515. < The> possible role of Visceral Adiposity in development of pro-atherogenic lipid profile in normal overweight young Egyptian female adults [a possible involvement of …
    516. Risk of early atherosclerosis by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease and low Visceral Adiposity
    517. … for early gastric cancer is associated with decreased cardiovascular mortality in accordance with amelioration of metabolic abnormalities, Visceral Adiposity and …
    518. Correlation of computerized tomography measurement of Visceral Adiposity with plasma adiponectin levels and presence of metastatic disease in patients with clear …
    519. The Findrisc score, Visceral Adiposity, insulin sensitivity and secretion estimates are independent predictors of type 2 diabetes in obese and overweight subjectsA
    520. Anthropometric correlates of total body fat, Visceral Adiposity and cardio-metabolic health risk: a community cohort study of urban, adult Sri Lankans
    521. The processing of wheat bran to release bound phenolic compounds improves insulin resistance and reduces Visceral Adiposity and liver cholesterol in ZDF rat
    522. Routine clinical measures of Adiposity as predictors of Visceral fat in adolescence: a population-based magnetic resonance imaging study
    523. Alternate‐day fasting and daily calorie restriction similarly affect Visceral Adiposity and circulating inflammatory cytokine concentrations
    524. Liver fat, Visceral Adiposity, and sleep disturbances contribute to the development of insulin resistance and glucose intolerance in nondiabetic dialysis patients
    525. … TESTING AND SYMPTOM EVALUATION IN CHRONIC RESPIRATORY DISEASE: Evaluation Of Cardiometabolic Risk Profile And Visceral Adiposity In Patients With …
    526. Abdominal Visceral Adiposity, Fatty Liver and Renin-Angiotensin-Aldosterone System: The Jackson Heart Study
    527. 190: Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Presence of Metastatic Disease in Patients with Clear …
    528. P. 084 Visceral Adiposity AS THE MAIN DETERMINANT OF CAROTID STIFFNESS IN A HEALTHY POPULATION WITH A WIDE BMI AND AGE RANGE …
    529. POD-6.11: Computerized Tomography Measurement of Visceral Adiposity Predicts Plasma Adiponectin Levels and Presence of Metastatic Disease in Patients with …
    530. Visceral fat but not general Adiposity is a predictor of sub-clinical atherosclerosis in HIV-infected patients with lipodystrophy.
    531. Are Changes In 25 (OH) Vitamin D Levels And Changes In Insulin Secretion Mediated By Changes In Visceral Adiposity? Results From A Lifestyle Intervention …
    532. Multiparity Is Associated with Type 2 Diabetes Independent of Adiponectin and Visceral Adiposity.
    533. Insulin Resistance (IR) and β-Cell Dysfunction, but not Visceral Adiposity, Predict New Onset Diabetes in Hispanics (HA) and African Americans (AA): The IRAS Family …
    534. GQ‐16, a novel partial PPARγ ligand, decreases Visceral Adiposity and induces the expression of thermogenesis‐related genes in mice with obesity and insulin …
    535. Visceral and subcutaneous Adiposity and adiponectin in middle‐aged Japanese men: the ERA JUMP study
    536. Differential effect of marrow Adiposity and Visceral and subcutaneous fat on cardiovascular risk in young, healthy adults
    537. Abdominal Adiposity with respect to the proportion of intra-abdominal Visceral fat to extra-abdominal fat (VS ratio) in Japanese childhood obesity
    538. A pilot investigation of Visceral fat Adiposity and gene expression profile in peripheral blood cells
    539. PP. 05.24: THE SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR EMPAGLIFLOZIN REDUCES WEIGHT AND MARKERS OF Visceral Adiposity IN TYPE 2 …
    540. Effects of short (12 months) and long (60 months) term treatment with cabergoline on metabolic syndrome and Visceral Adiposity index in patients with …
    541. Chitinase 3 Like 1 (CHI3L1) Is A Critical Regulator Of Visceral Adiposity And The PPAR Pathway
    542. Visceral and subcutaneous Adiposity and brachial artery vasodilator function
    543. Ultrasound measurements of Visceral and subcutaneous abdominal thickness to predict abdominal Adiposity among older men and women
    544. Study on correlation of abdominal height with Visceral fat area and the cutoff points to predict abdominal Adiposity
    545. Analysis of Visceral and subcutaneous Adiposity via micro-computer tomography
    546. Anthropometric Measures of Adiposity as Predictors of Visceral and Subcutaneous Fat in Adolescence: The Saguenay Youth Study
    547. Short-term effects of liraglutide on Visceral fat Adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
    548. Treatment of obese diabetic mice with a heme oxygenase inducer reduces Visceral and subcutaneous Adiposity, increases adiponectin levels, and improves insulin …
    549. Effects of microvascular complications on structural changes in Visceral and subcutaneous Adiposity among type 2 diabetes patients
    550. FTIR imaging of structural changes in Visceral and subcutaneous Adiposity and brown to white adipocyte transdifferentiation
    551. Insulin therapy induced Adiposity evaluated by computed tomography is not Visceral
    552. Switch to Raltegravir from PI or NNRTI Does Not Reduce Visceral Fat in HIV-Infected Women with Central Adiposity
    553. … inhibitor or nonnucleoside reverse-transcriptase inhibitor does not reduce Visceral fat in human immunodeficiency virus-infected women with central Adiposity
    554. In adult twins, Visceral fat accumulation depends more on exceeding sex-specific Adiposity thresholds than on genetics
    555. Insulin therapy induced Adiposity evaluted by computed tomography is not Visceral
    556. A Pilot Investigation of Visceral Fat Adiposity and Gene Expression Profile in Peripheral Blood Cells
    557. Increasing Adiposity in normal ovulatory women affects adipocytokine expression in subcutaneous and Visceral abdominal fat
    558. Visceral and Abdominal Adiposity Using Thoracic-Abdominal Profile Image Acquisition database
    559. Subcutaneous and Visceral adipose tissue FTO gene expression and Adiposity, insulin action, glucose metabolism, and inflammatory adipokines in type 2 diabetes …
    560. Carotid IMT values are related to insulin resistance and Visceral disposition of Adiposity in obese patients
    561. Diet-induced alterations in energy homeostasis and central Adiposity: liver and Visceral adipose tissue
    562. Liver Enzymes Correlate with Visceral but not Subcutaneous Adiposity: the IRAS Family Study.
    563. Corrigendum: Visceral and Subcutaneous Adiposity and Adiponectin in Middle-aged Japanese Men: The ERA JUMP Study
    564. Lipolysis, lipogenesis, and Adiposity are reduced while fatty acid oxidation is increased in Visceral and subcutaneous adipocytes of endurance-trained rats
    565. … of 11β-hydroxysteroid dehydrogenase type 1 in Visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with Adiposity
    566. Genome-wide blood leukocyte DNA methylation in relation to Visceral, subcutaneous, and hepatic Adiposity in postmenopausal women.
    567. Suppression of isoproterenol-induced lipolysis by insulin in rat Visceral adipose tissue explants is increased with aging: Consequences on Adiposity
    568. Baseline and Change in Visceral and Subcutaneous Adiposity Predict Future HDL Cholesterol, Triglycerides, and non HDL Cholesterol Levels in Japanese …
    569. Treatment of Obese Diabetic Mice with an Heme Oxygenase Inducer Reduces Visceral and Abdominal Adiposity, Increases Adiponectin Levels and Improves Insulin …
    570. 475: ABDOMINAL Visceral AND SUBCUTANEOUS Adiposity ARE ASSOCIATED WITH ACUTE KIDNEY INJURY IN CRITICALLY ILL TRAUMA PATIENTS
    571. Contribution of genetics to Visceral Adiposity and its relation to cardiovascular and metabolic disease
    572. Computed tomography highlights increased Visceral Adiposity associated with critical illness in COVID-19
    573. Visceral Adiposity elevates the risk of critical condition in COVID‐19: A systematic review and meta‐analysis
    574. Visceral Adiposity index and 10-year cardiovascular disease incidence: the ATTICA study
    575. The role of Visceral Adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany
    576. The fat of the matter: obesity and Visceral Adiposity in treated HIV infection
    577. Visceral Adiposity and sarcopenic Visceral obesity are associated with poor prognosis after resection of pancreatic cancer
    578. Visceral Adiposity predicts post‐operative Crohn’s disease recurrence
    579. Visceral Adiposity and cancer survival: a review of imaging studies
    580. Visceral Adiposity, subcutaneous Adiposity, and severe coronavirus Disease-2019 (COVID-19): systematic review and meta-analysis
    581. Derivation and validation of a new Visceral Adiposity index for predicting Visceral obesity and cardiometabolic risk in a Korean population
    582. Exercise reduces liver lipids and Visceral Adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial
    583. Visceral Adiposity and high intramuscular fat deposition independently predict critical illness in patients with SARS‐CoV‐2
    584. Visceral Adiposity, genetic susceptibility, and risk of complications among individuals with Crohn’s disease
    585. Association between blood mercury level and Visceral Adiposity in adults
    586. Heart rate variability reduction is related to a high amount of Visceral Adiposity in healthy young women
    587. New indexes of body fat distribution, Visceral Adiposity index, body Adiposity index, waist-to-height ratio, and metabolic disturbances in the obese
    588. Visceral Adiposity predicts severity of acute pancreatitis
    589. Low skeletal muscle radiation attenuation and Visceral Adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer
    590. Associations between abdominal obesity indices and diabetic complications: Chinese Visceral Adiposity index and neck circumference
    591. Visceral Adiposity index as a predictor of NAFLD: A prospective study with 4‐year follow‐up
    592. Visceral Adiposity index is associated with lung function impairment: a population-based study
    593. Visceral Adiposity index (VAI), a powerful predictor of incident hypertension in prehypertensives
    594. Menopausal hormone therapy is associated with reduced total and Visceral Adiposity: the OsteoLaus Cohort
    595. Changes in Visceral Adiposity, subcutaneous Adiposity, and sex hormones in the diabetes prevention program
    596. Visceral Adiposity index as a predictor for type 2 diabetes mellitus in Asian population: a systematic review
    597. The use of Visceral Adiposity variables in the prediction of obstructive sleep apnea: evidence from a large cross-sectional study
    598. Obesity, Visceral Adiposity and carotid atherosclerosis
    599. Fructose-induced inflammation and increased cortisol: A new mechanism for how sugar induces Visceral Adiposity
    600. Visceral Adiposity index predicts the conversion of metabolically healthy obesity to an unhealthy phenotype
    601. Impact of Visceral Adiposity on severity of acute pancreatitis: a propensity score-matched analysis
    602. Chinese Visceral Adiposity index: A reliable indicator of Visceral fat function associated with risk of type 2 diabetes
    603. Low plasma adiponectin concentrations predict increases in Visceral Adiposity and insulin resistance
    604. Validity of Visceral Adiposity estimates from DXA against MRI in Kuwaiti men and women
    605. Visceral Adiposity index as an independent marker of subclinical atherosclerosis in individuals prone to diabetes mellitus
    606. Visceral Adiposity links cerebrovascular dysfunction to cognitive impairment in middle-aged mice
    607. A Novel Visceral Adiposity Index for Prediction of Type 2 Diabetes and Pre-diabetes in Chinese adults: A 5-year prospective study
    608. Visceral Adiposity index as a useful tool for the assessment of cardiometabolic disease risk in women aged 65 to 74
    609. Association between coronary atherosclerosis and Visceral Adiposity index
    610. Adiponectin expression in Visceral Adiposity is an important determinant of insulin resistance in morbid obesity
    611. Fibroblast growth factor receptor is a mechanistic link between Visceral Adiposity and cancer
    612. Effect of exercise and pharmacological interventions on Visceral Adiposity: a systematic review and meta-analysis of long-term randomized controlled trials
    613. Comparisons of Visceral Adiposity index, body shape index, body mass index and waist circumference and their associations with diabetes mellitus in adults
    614. Effects of Visceral Adiposity on glycerol pathways in gluconeogenesis
    615. Visceral Adiposity and me